ArticleCurrent research in microbial sciences2026
Gut microbial allies and adversaries in SARS-CoV-2 infection.
Article in Current research in microbial sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the immediate threat of coronavirus disease 2019 (COVID-19) has diminished, the World Health Organization (WHO) still considers it an important public health concern, as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to circulate at considerable levels. The gut plays an important role in host responses to viral infections, yet its functional role in SARS-CoV-2 infection remains largely unexplored. We conducted a cross-sectional study, including 63 SARS-CoV-2-positive patients and 54 healthy controls, to identify differences in clinically relevant parameters (biochemical and haematological) and in gut microbiota composition, analysed by full-length ribosomal ribonucleic acid (rRNA) operon amplicon sequencing (16S-ITS-23S) on the MinION platform. To evaluate the ability of commensal bacteria inversely associated with COVID-19 to modulate the immune response and intercept SARS-CoV-2's cell entry and infectivity, we performed functional
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.